In a remarkably short interval of time, pulmonary artery hypertension (PAH) has evolved from
a disease of unknown pathogenesis devoid of effective therapy to a condition whose cellular …

Pulmonary arterial hypertension (PAH) is an enigmatic and deadly vascular disease with no
known cure. Recent years have seen rapid advances in our understanding of the molecular …

The pathobiology of pulmonary arterial hypertension (PAH) is complex and incompletely
understood. Although three pathogenic pathways have been relatively well characterised, it …

Pulmonary arterial hypertension (PAH) is a vascular remodeling disease that pathologically
increases pulmonary vascular resistance. Ultimately, this leads to right ventricular failure …

Pulmonary arterial hypertension (PAH), the first category of pulmonary hypertension, is a
chronic and progressive disorder characterised by angioproliferative vasculopathy in the …

While there have been advances in the field of pulmonary arterial hypertension (PAH),
disease management remains suboptimal for many patients. The development of novel …

Until 20 years ago the treatment of pulmonary arterial hypertension (PAH) was based on
case reports and small series, and was largely ineffectual. As a deeper understanding of the …

Pulmonary arterial hypertension (PAH) is a complex obliterative vascular disease. It remains
deadly despite an explosion of basic research over the past 20 years that identified myriads …

Pulmonary arterial hypertension (PAH) is a rare yet serious progressive disorder that is
currently incurable. This female-predominant disease unfolds as a pan-vasculopathy that …

Pulmonary arterial hypertension (PAH) is a debilitating multifactorial disease characterized
by progressive pulmonary vascular remodeling, elevated pulmonary arterial pressure, and …